First to clinics support for biologics in - Innovative and biosimilar biologics molecules (mammalian and microbial origin) - USP/DSP process development speed up - CDMO selection and evaluation - Technological fit evaluation - Comparability and biosimilarity strategy - Regulatory CMC pathway and support - Facility readiness support for regulatory inspections - Mock inspections for EMA and FDA submissions